AGP Picks
View all

Science Times Observer: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Science Times Observer.

Press releases published on July 29, 2026

Global Study: Poor-Quality AI Content Puts Brand Trust at Risk
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
Calian to Hold Conference Call Following Announcement of Third Quarter FY 2026 Results
Calian tiendra une conférence téléphonique après l’annonce des résultats du troisième trimestre de l’exercice 2026
Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
Realize Medical Appoints Chris Marrus to Board of Directors
Advantage Solutions to Participate in The Canaccord Annual Growth Conference on August 12, 2026
Viasat Sets August 4, 2026, for First Quarter Fiscal Year 2027 Financial Results Conference Call and Webcast
QuasarMD Launches New Full-Body Red Light Therapy Mat to Expand Its At-Home Wellness Line
LB Pharmaceuticals Announces $150 Million Private Placement
EagleNXT Releases a New, Updated Version of the MicaSense RedEdge-MX Multispectral Sensor
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones
EDMO Expands System Intelligence Layer to Simplify Higher Education Admissions
Mobilicom to Participate in Premier U.S. DoW Exercise: Northern Strike 2026
Multibeam Signs $140 Million Letter of Intent with the U.S. Department of Commerce
Quantum Cyber Applauds President Trump's Drone Dominance Program and Supply Chain Framework, Reaffirms Commitment to On-Shore U.S. Manufacturing of Autonomous Systems
OptimizeRx Sets Second Quarter 2026 Conference Call for August 12, 2026, at 4:30 p.m. ET
3D Systems’ Saudi Arabian Joint Venture NAMI Obtains Critical Military Manufacturing License for Local Defense Hardware Production
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Science Times Observer

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.